Veniti, the developer of a patented venous stent system, has secured $25 million in funding from Boston Scientific Corp. The company will use the investment to complete a trial and regulatory filing for its stent system as well as grow its product line and commercial operations.
The firm's stent system, called Vici, was designed to overcome the challenges of durability and ease of use physicians face when working with stents with the millions of patients affected by venous disease worldwide, according to a statement from Veniti.
The FDA Investigational Device Exemption study will include 200 patients and take place over the course of 60 months to ensure patient safety post-surgery.
Last year, Veniti raised more than $17 million from various life sciences venture capital firms to demonstrate patient benefit from its Vici stent system.